CNS Pharmaceuticals announces USFDA approval of IND application for its brain cancer drug candidate Berubicin
CNS Pharma will initiate its trial during the first quarter of 2021 to investigate the efficacy of Berubicin in adults with GBM who have failed ...
Dec 18